We further illustrated this using a preclinical murine model of Burkitt’s lymphoma (Eμ-myc; p19Arf−/−), where treatment of an admixed heterogeneous tumor population with olaparib (a case of a differential selective pressure regimen) led to much greater resistance potential than paclitaxel (a case of an equal selective pressure regimen). The gene discussed is MYC; the disease is Burkitt lymphoma.